The DOI matches its Crossref record.
Long-term weight control study I (weeks 0 to 34)
Abstract
To investigate the value of anorexiant medications as an adjunct to other forms of weight control therapy, we studied 121 people in a 34-week, double-blind clinical trial of 60 mg extended-release fenfluramine plus 15 mg phentermine resin versus placebo added to behavior modification, caloric restriction, and exercise. Participants weighed 130% to 180% (154% +/- 1.2%, mean +/- SEM) of ideal body weight (1983 Metropolitan Life tables) and were in good health. By week 34, participants receiving active medication lost an average of 14.2 +/- 0.9 kg, or 15.9% +/- 0.9% of initial weight (n = 58), versus a loss of 4.6 +/- 0.8 kg or 4.9% +/- 0.9% of initial weight by subjects taking placebo (n = 54; p less than 0.001). On visual analog scales, participants rated fenfluramine plus phentermine as more helpful than placebo (50.3 +/- 0.5 versus 20.3 +/- 0.3) and not bothersome (fenfluramine plus phentermine, 17.4 +/- 0.3 versus 13.5 +/- 0.2). Blood pressure decreased and pulse remained unchanged in both groups. Dry mouth was the most common adverse effect in subjects receiving fenfluramine plus phentermine; all adverse effects decreased after 4 weeks. Only nine participants left the study in the first 34 weeks. Two subjects from each group left the study as a result of adverse effects. Overall, fenfluramine plus phentermine used in conjunction with behavior modification, caloric restriction, and exercise aided weight loss and continued to be efficacious for 34 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Franz, M. J., Bantle, J. P., Beebe, C. A., Brunzell, J. D., Chiasson, J.-L., Garg, A., Holzmeister, L. A., Hoogwerf, B., Mayer-Davis, E., Mooradian, A. D., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.148 · Cited by 1,165
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Behavioral treatment of obesity
Butryn, M. L., Webb, V., & Wadden, T. A. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.08.006 · Cited by 636
Yanovski, S. Z., & Yanovski, J. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012586 · Cited by 544
Anti-obesity drugs: past, present and future
Rodgers, R. J., Tschöp, M. H., & Wilding, J. P. H. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.009621 · Cited by 430
Current pharmacotherapy for obesity
Srivastava, G., & Apovian, C. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.122 · Cited by 397
Sibutramine Produces Dose‐Related Weight Loss
Bray, G. A., Blackburn, G. L., Ferguson, J. M., Greenway, F. L., Jain, A. K., Mendel, C. M., Mendels, J., Ryan, D. H., Schwartz, S. L., Scheinbaum, M. L., et al. (1999) · Obesity Research · doi:10.1002/j.1550-8528.1999.tb00701.x · Cited by 382
Bray, G. A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., & Perry, B. H. (2003) · Obesity Research · doi:10.1038/oby.2003.102 · Cited by 344
Current and Potential Drugs for Treatment of Obesity
Bray, G. A., & Greenway, F. L. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0383 · Cited by 331
Medical and surgical options in the treatment of severe obesity
Fisher, B. L., & Schauer, P. (2002) · The American Journal of Surgery · doi:10.1016/s0002-9610(02)01173-x · Cited by 316
Behavioral Treatment of Obesity
Wadden, T. A., & Foster, G. D. (2000) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70230-3 · Cited by 309
Khan, M. A., Herzog, C. A., St. Peter, J. V., Hartley, G. G., Madlon-Kay, R., Dick, C. D., Asinger, R. W., & Vessey, J. T. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391101 · Cited by 265
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Behavioral treatment of obesity: thirty years and counting
Wilson, G. T. (1994) · Advances in Behaviour Research and Therapy · doi:10.1016/0146-6402(94)90002-7 · Cited by 159
Pharmacological Therapies for Obesity
Kaplan, L. M. (2005) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2004.12.002 · Cited by 149
Bray, G. A., & Ryan, D. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14200 · Cited by 148
Hendricks, E. J., Greenway, F. L., Westman, E. C., & Gupta, A. K. (2011) · Obesity · doi:10.1038/oby.2011.94 · Cited by 97
Mechanick, J. I., Brett, E. M., Chausmer, A. B., Dickey, R. A., Wallach, S., Bergman, D. A., Garber, J. R., Hamilton, C. R., Handelsman, Y., Holdy, K. E., et al. (2003) · Endocrine Practice · doi:10.4158/ep.9.5.417 · Cited by 73
The new era of drug therapy for obesity: the evidence and the expectations
Jones, B. J., & Bloom, S. R. (2015) · Drugs · doi:10.1007/s40265-015-0410-1 · Cited by 58
Behavioural treatment of the overweight patient
Wadden, T. A., Sarwer, D. B., & Berkowitz, R. I. (1999) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1053/beem.1999.0008 · Cited by 48
The past, present, and future of behavioral obesity treatment
Chao, A. M., Moore, M., & Wadden, T. A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01525-3 · Cited by 40
Benefits of Lifestyle Modification in the Pharmacologic Treatment of Obesity: A Randomized Trial
Wadden, T. A., Berkowitz, R. I., Sarwer, D. B., Prus-Wisniewski, R., & Steinberg, C. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.2.218 · Cited by 1
Metadata
- Authors
- Weintraub, M., Sundaresan, P. R., Madan, M., Schuster, B., Balder, A., Lasagna, L., & Cox, C.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1992-05
- Volume
- 51
- Issue
- 5
- Pages
- 586-594
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1966193292
- Cited by
- 173
- References
- 0
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.